EART yields 0.60% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, EART + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EART + ABBV for your $10,000?
DMAT tracks an index of global stocks that produce metals and other raw materials essential to the expansion of disruptive technologies. Disruptive Materials Companies derive at least 50% of their revenues from the exploration, mining, production and/or enhancement of one or more of 10 materials categories that include Rare Earth Materials, Lithium, Copper, Carbon Fiber, etc. Stocks not meeting the revenue requirements are considered after review and recognized as Pre-Revenue Disruptive Materials Companies. In the case of Lithium, stocks with associated revenue between 25-50% are also eligible as Diversified Lithium Companies. The fund uses a natural language processing algorithm to identify and rank stocks. The five highest-ranked Disruptive Materials and Pre-Revenue Disruptive Materials Companies per materials category are selected. The fund employs a modified market-cap weighting scheme for diversification. The index is reconstituted and rebalanced semi-annually.
Full EART Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.